Purpose
Stay up-to-date on getting recommended vaccines. View and Print CDC immunization schedules for those ages 19 Years or Older.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Vaccines in the Adult Immunization Schedule*
(See Addendum)
Vaccines | Recommendations | Effective Date of Recommendation* |
---|---|---|
COVID |
|
February 28, 2024 |
COVID-19 (Moderna, Pfizer-BioNTech, Novavax) |
ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥6 months of age. | June 27, 2024 |
Influenza |
|
June 27, 2024 |
Pneumococcal conjugate vaccine | ACIP recommends PCV21 as an option for adults aged ≥19 years who currently have a recommendation to receive a dose of PCV. | June 27, 2024 |
Respiratory syncytial virus vaccine (RSV) |
a RSV vaccination is recommended as a single lifetime dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose. b These recommendations supplant the current recommendation that adults 60 years of age and older may receive RSV vaccination, using shared clinical decision-making. Adults 60–74 years of age who are not at increased risk of severe RSV disease are NOT recommended to receive RSV vaccination. CCDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation. |
June 26, 2024 |
*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.
*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.